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Abstract 
 
Background: Herbal products of questionable quality create major concern for human population since their production is often not 
controlled and regulated.  
Material and Methods: Antihypertensive herbal products were subjected to pharmaceutical quality control parameters specified in 
Pharmacopoeias, toxic quantification of heavy metals by flame atomic absorption spectrophotometer and adulterated allopathic 
contents were quantified using advanced HPLC techniques.  
Results: A lot of variations in pharmaceutical parameters like moisture contents and LOD% values were observed. Also deviations 
to a greater extent in weight variation, (P1, P2, P6, P12, P16, P17, P19, and P20), and hardness of the tablets of products (P1, P3, P8 
and P11) were found. Friability of tablets of the Products (P3, P9 and P11) was found failed. Heavy metals i-e Fe (1597.20ppm, 
1648ppm) in P5, P9, Pb (61.32ppm, 16.59 ppm) in P5, Cr (96.91ppm ,108.48 ppm) in P4, P14, Cd (39.53ppm, 32.31 ppm) in P11, 
P12, Cu (28.22ppm, 21.04 ppm) in P15, P17, Zn (80.31ppm,76.27 ppm) in P15, P16, Ni (45.46ppm,22.18ppm) in P9, P13 in toxic 
concentrations were detected. Adulterated allopathic contents of Amlpdopine in higher quantities, administered according to 
manufacturer dose were found in P12 (20.30 mg/day), Verapamil in P2 (93.50 mg/day), Nifedipine (38.65 mg/day) in P6. Products 
P4, P5 and P7 were found to have a combination of Amlodipine and Hydrochlorothiazide and higher concentrations were found in 
P5 (10.72 mg/day, 24.75 mg/day).  
Conclusion:. The antihypertensive herbal products contained different kind of adulterants. Our findings suggest that effective 
regulatory measures should be put in place to address this problem. This will help to decrease the toxic effects of these remedies and 
increase the commercialization, internationalization and harmonization of antihypertensive herbal products. 
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Introduction 
 
 The prevalence of hypertension is increasing across the globe and its control rates remains low (Gallagher et al., 2006). 
Despite the fact that a variety of consistent guidelines are available for the treatment of hypertension, the problem of insufficient 
management still persists (Selvam et al., 2010). Herbal medicines are widely consumed the world over, for primary healthcare 
because of their better acceptability within the human body, higher safety margins and less cost (Dasgupta, 2003). Such increase in 
popularity has also brought concerns and fears regarding the quality, efficacy and safety of herbal and natural sources available in 
the market (Schuppan et al., 1999). The use of herbal remedies of questionable quality exposes human population to multiple risks 
and creates major concern for various health agencies on national and international level (Barnes, 2003). The quality of herbal 
products remains poor because their production is often not controlled or regulated (Rousseaux and Schachter, 2003). Therefore 
screening of traditional remedies for efficacy and safety has been recommended to protect public health (Calixto, 2000).  
These products may be contaminated with excessive or banned pesticides, heavy metals, chemical toxins and adulterated 
with undeclared allopathic contents (Chan, 2003). Additional contaminants like particulate matters may also be introduced during 
handling and production of herbal medicines since no conscious efforts are made to decontaminate them (Lenaghan et al., 2009). 
Therefore, an effective and advanced quantification method is needed to monitor the levels of various adulterants in herbal 
medicines (Klinsunthorn et al., 2011). Herbal medicines are commonly used and the idea about its potential toxicity is not very well 
known which often lead to improper use of such remedies (Khalil et al., 2014). Increased reports on side effects and the adulteration 
of herbal drugs the world over have raised concerns on its use (Niggemann and Grüber, 2003).  
Therefore an attempt is made for the identification and quantification of selected antihypertensive herbal products both raw 
material and finished dosage form, for their pharmaceutical quality control parameters, toxic heavy metals and undeclared 
adulterated allopathic drug contents.  
 
 
Material and Methods 
Pharmaceutical parameters 
 
 The pharmaceutical parameters like melting point, pH value, bulk density, tap density, LOD% and moisture content of raw 
materials and parameters like gelatin identification test for capsule shells, weight variation, diameter, thickness, hardness and 
friability of the tablets of finished dosage form were determined by standard methods available in Pharmacopoeia. Melting point was 
determined by melting point apparatus, pH value by pH meter, bulk density and tap density by density measure equipment, loss on 
drying by LOD equipment and moisture contents by Carl Fischer.  For identification of gelatin the capsule shells were weighed and 
dissolve in 100 ml of hot water. The solution was then placed in refrigerator (2-10°C) for 4 hours. The gelled solution was then 
removed and placed in a container at 60°C for 30 minutes, when stirred, the gel reverts to the original liquid state (USP, 2014). 
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Weight variation was determined by electronic analytical balance (USP, 2014). Diameter and thickness were calculated by Vernier 
caliper (USP, 2014). Hardness of tablets was determined by Monsanto tester. Friability of the tablets was determined using friability 
tester i-e Erweka tablets friability tester (USP, 2014). 
 
Toxic heavy metals evaluation by flame atomic absorption spectrophotometer 
 
 The herbal drug products were ground and about one gram (1g) was taken and added in 10 ml of concentrated Nitric acid 
solution (67%) in a conical flask and kept overnight at room temperature. After 24 hrs about 4 ml perchloric acid was added and 
heated till one (1ml) solution remained in the flask. It was then cooled, diluted with deionized water and filtered via Whatmann filter 
paper. Finally 100 ml volume was made by deionized water. The prepared samples were then analyzed by flame atomic absorption 
spectrophotometer for determination of toxic heavy metals (Saeed et al., 2010).  
 
Adulterated allopathic contents evaluation by HPLC 
 
 The liquid chromatography system consisted of an isocratic pump (Model SPD 10AV-VP) UV-Visible detector 
(Schimadzo), LC-10AT VP, Column C18 (Thermo scientific) was used. For Amlodipine identification, the mobile phase consists of; 
Methanol, acetonitrile, and Buffer (35:15:50). For Verapamil mobile phase was Acetonitrile, 2-aminoheptane and buffer (60:1:140) 
while for Nifedipine, Acetonitrile, methanol, and water (25:25:50). Hydrochlorothiazide identification was carried out using mobile 
phase (0.1 M monobasic sodium phosphate and acetonitrile (9:1 adjust with phosphoric acid to a pH 3.0 ±0.1). UV detection was 
conducted at 237 nm for Amlodipine, 278 nm for Verapamil, 265 nm for Nifedipine and 254 nm for hydrochlorothiazide (USP, 
2014) 
 
Table 1: Pharmaceutical properties of local herbal anti hypertensive raw materials 
 
Product 
Code 
Appearance Melting 
Point (C0) 
PH Value  
(1dose/100ml in 
D/W 
Bulk 
Density 
(mg/ml) 
Tap 
Density 
(mg/ml) 
LOD 
(%) 
Moisture 
Contents 
(%) 
P1 Brown 
Amorphous 
238±0.05 5.96±0.0 0.843±0.0 0.767±0.0 6.79±0.0 6.38±0.04 
P2 White 
Homogenous 
242±0.0 6.70±0.01 0.976±0.0 0.846±0.0 5.96±0.03 5.84±0.02 
P3 White Granules 279±0.1 5.73±0.0 0.986±0.0 0.887±0.0 6.49±0.02 6.11±0.06 
P4 White 
homogenous 
Powder 
253±0.57 6.11±0.0 0.976±0.0 0.794±0.0 4.37±0.03 4.30±0.02 
P5 Brown 
amorphous 
Powder 
189±0.0 7.02±0.01 0.736±0.0 0.679±0.0 8.00±0.01 7.87±0.04 
P6 Brown fibrous 
Powder 
208±0.57 5.88±0.01 0.983±0.0 0.876±0.0 6.11±0.02 5.84±0.03 
P7 White Powder 194±0.05 5.46±0.01 0.967±0.0 0.843±0.0 5.35±0.02 5.27±0.03 
P8 Brown granules 234±0.0 5.27±0.0 0.739±0.0 0.687±0.0 4.76±0.0 3.96±0.02 
P9 Amorphous 
Powder 
273±0.1 6.11±0.0 0.847±0.0 0.769±0.0 5.73±0.01 5.48±0.02 
P10 Dark brown 
Powder 
235±0.0 7.30±0.01 0.884±0.0 0.762±0.0 4.88±0.01 4.29±0.01 
P11 Dark brown 
Powder 
271±0.5 6.80±0.0 0.936±0.0 0.843±0.0 3.97±0.03 3.88±0.04 
P12 White granules 219±0.5 5.70±0.0 0.946±0.0 0.837±0.0 6.76±0.0 6.67±0.0 
P13 Brown Powder 247±0.05 5.64±0.0 0.976±0.0 0.939±0.0 5.28±0.01 5.01±0.01 
P14 Metallic green 
powder 
236±0.0 6.34±0.02 0.949±0.0 0.913±0.0 4.39±0.02 4.24±0.02 
P15 White fine 
Powder 
274±0.0 7.11±0.01 0.984±0.0 0.947±0.0 7.33±0.01 7.04±0.02 
P16 Metallic brown 
Powder 
227±0.0 6.84±0.02 0.849±0.0 0.814±0.0 5.76±0.0 5.48±0.01 
P17 White Powder 277±0.0 5.94±0.02 0.973±0.0 0.949±0.0 5.14±0.02 5.01±0.01 
P18 Greenish 
granules 
264±0.0 5.76±0.03 0.931±0.0 0.916±0.0 6.39±0.0 6.22±0.01 
P19 Brown granules 208±0.0 6.84±0.0 0.967±0.0 0.926±0.0 8.00±0.01 7.76±0.0 
P20 White 
homogenous 
powder 
287±0.0 6.73±0.01 0.964±0.0 0.949±0.0 3.96±0.02 3.71±0.0 
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Results and Discussion 
 
 The herbal remedies indicated for hypertension when subjected to the same physicochemical tests conducted for allopathic 
drugs, fails a variety of tests (Table 1 and 2). High moisture contents promote microbial growth and may result to infectious 
diseases. A lot of variation in weight, hardness, thickness, diameter and friability of tablets were found in herbal dosage forms. Also 
the drug product supplied in capsule dosage form (P16) failed the gelatin identification test. The physicochemical parameters are 
important given that therapeutic remedies fail such tests which may lead to toxicity or deficient pharmacological effects. 
Table 2: Pharmaceutical Properties of local herbal antihypertensive finished dosage forms 
Product 
Code 
Dosage 
Form 
Gelatin 
Test 
Average Weight 
(mg) 
Average 
Diameter 
(mm) 
Average 
Thickness 
(mm) 
Average 
Hardness 
(Kg) 
Friability (%) 
P1 Tablet NA 732.10±26.36 9.39±0.32 6.15±0.05 16.0±1.63 0.09 
P2 Tablet NA 604.00±23.16 6.72±0.41 4.37±0.32 15.0±2.62 0.06 
P3 Tablet NA 523.60±7.05 5.95±0.07 3.42±0.06 2.51±0.48 Failed 
P4 Tablet NA 577.60±8.26 4.78±0.22 3.50±0.10 14.0±0.81 0.04 
P5 Tablet NA 409.20±8.43 4.06±0.26 4.65±0.05 11.2±0.71 0.73 
P6 Tablet NA 878.20±14.12 8.9±0.18 5.26±0.06 12.0±0.95 0.98 
P7 Tablet NA 898.70±5.34 9.97±0.13 4.09±0.08 9.0±1.33 0.42 
P8 Tablet NA 264.60±7.63 3.91±0.12 1.08±0.08 5.10±0.14 0.43 
P9 Tablet NA 306.80±4.6 3.57±0.11 3.45±0.05 5.0±0.89 Failed 
P10 Capsule (+) 500.20±15.57 NA NA NA NA 
P11 Tablet NA 462.20±5.05 5.32±0.26 5.43±0.07 3.47±1.05 Failed 
P12 Capsule (+) 897.10±13.93 NA NA NA NA 
P13 Capsule (+) 556.1±8.06 NA NA NA NA 
P14 Capsule (+) 659.70±5.64 NA NA NA NA 
P15 Tablets NA 221.50±6.83 3.09±0.1 5.17±0.06 12.20±2.2 0.76 
P16 Capsule (–) 747.50±15.14 NA NA NA NA 
P17 Tablets NA 649.90±14.04 5.79±0.15 3.43±0.04 7.50±0.67 0.87 
P18 Capsule (+) 849.70±14.59 NA NA NA NA 
P19 Capsule (+) 903.10±15.98 NA NA NA NA 
P20 Capsule (+) 789.30±21.36 NA NA NA NA 
NA= Not Applicable, (+) = Pass gelatin Identification Test, (-) = Failed gelatin Identification Test 
Pharmaceutical evaluation of raw materials and finished dosage form   
Melting Point 
 
 Melting points of raw materials of herbal antihypertensive products were determined by melting point apparatus (USP, 
2014).  Melting points of all the tested samples are given in Table 1.  
 
 pH value 
 
Tables 1, show all the pH values determined by pH meter (USP, 2014).  
 
 Bulk density and Tap density 
 
 The bulk and tap densities were obtained (Table 1) by dividing the weight of the sample in grams by the final volume in 
cm3 of   the sample contained in the cylinder (USP, 2014). 
 
 Loss on drying (LOD %) and Moisture contents 
 
 LOD % and moisture contents of the raw materials of antihypertensive herbal products were determined (Table 1) using 
LOD and Karl Fisher method (USP, 2014).  
  
 Gelatin Identification test 
 
From Table 2, it was observed that that only product P16 failed gelatin test (USP, 2014). 
 
Weight variation  
 
 With the help of electronic balance average weight of the tablets were determined (USP, 2014). Table 2 shows greater 
weight variation in products, P1, P2, P6, P12, P16, P17, P19 and P20.  
 
 Diameter and Thickness of tablets 
The diameter and thicknesses of the tablets were determined by using Vernier caliper. Average diameter and thickness 
values were calculated (USP, 2014) as shown in Table 2. 
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Table 3: Concentration (ppm) of various toxic heavy metals in raw material of local antihypertensive herbal drug products 
Product code          Fe         Cd         Pb        Cr        Cu       Mn        Zn        Ni 
P1 984 ± 9.12 17.50 ± 2.33 2.790 ± 0.0 1.743 ± 0.07 15.08 ± 0.91 43.96 ± 3.721 27.32 ± 0.82 0.5567 ± 0.13 
P2 48.96 ± 4.11 40.24 ± 3.98 ND 2.593 ± 0.25 4.213 ± 0.07 19.12 ± 0.78 10.41 ± 0.50 19.60 ± 2.16 
P3 314.8 ± 6.37 5.893 ± 1.05 2.010 ± 0.12 19.55 ± 1.70 0.5467 ± 0.07 ND 0.380 ± 0.11 2.513 ± 0.78 
P4 1574 ± 5.36 32.42 ± 2.32 6.250 ± 0.20 ND 4.170 ± 0.13 20.09 ± 0.92 6.597 ± 0.80 3.083 ± 0.11 
P5 836.60 ± 11.84 2.343 ± 0.78 7.063 ± 0.40 76.44 ± 0.35 7.767 ± 0.18 13.66 ± 1.51 14.98 ± 1.53 2.067 ± 0.17 
P6 141.6 ± 1.24 5.370 ± 0.16 ND 5.573 ± 0.34 2.300 ± 0.25 12.68 ± 0.61 3.640 ± 0.38 8.450 ± 0.20 
P7 48.19 ± 2.95 8.023 ± 1.01 0.550 ± 0.19 113.9 ± 4.42 1.447 ± 0.02 7.910 ± 0.74 5.487 ± 0.29 1.230 ± 0.09 
P8 91.25 ± 1.41 8.200 ± 0.51 1.530 ± 0.18 118.8 ± 3.91 5.440 ± 0.14 14.80 ± 0.26 33.62 ± 2.29 22.85 ± 1.61 
P9 1565 ± 62.36 3.003 ± 0.50 85.33 ± 7.52 96.25 ± 3.55 2.403 ± 0.27 22.73 ± 3.20 8.457 ± 0.58 2.267 ± 0.18 
P10 36.45 ± 1.99 10.35 ± 0.52 ND 23.49 ± 1.25 29.55 ± 2.16 22.45 ± 1.13 81.98 ± 3.26 0.150 ± 0.03 
P11 77.29 ± 1.07 4.860 ± 0.22 85.26 ± 4.13 ND 1.600 ± 0.21 16.43 ± 0.80 7.847 ± 0.63 9.043 ± 0.16 
P12 763.3 ± 15.61 4.703 ± 0.51 ND 14.43 ± 0.68 4.763 ± 0.13 3.547 ± 0.17 79.61 ± 3.71 0.743 ± 0.16 
P13 268.20 ± 20.43 5.613 ± 0.14 4.680 ± 0.17 0.563 ± 0.04 2.590 ± 0.16 12.62 ± 0.68 9.860 ± 0.90 7.577 ± 0.12 
P14 14.62 ± 1.74 1.317 ± 0.25 0.353 ± 0.06 55.00 ± 3.06 22.71 ± 1.42 13.12 ± 1.70 31.75 ± 1.49 4.960 ± 0.23 
P15 66.70 ± 12.91 8.947 ± 1.40 1.403 ± 0.25 3.167 ± 0.00 2.593 ± 0.19 4.677 ± 0.21 22.75 ± 1.42 0.89±0.01 
P16 235.6 ± 12.76 8.357 ± 0.07 0.510 ± 0.19 0.583 ± 0.10 10.44 ± 0.60 8.767 ± 0.60 25.63 ± 0.57 5.090 ± 0.10 
P17 1615 ± 86.85 1.353 ± 0.23 1.503 ± 0.15 0.533 ± 0.09 4.497 ± 0.16 17.30 ± 0.65 8.400 ± 0.12 52.13 ± 1.19 
P18 569.1 ± 10.44 2.607 ± 0.20 8.153 ± 0.22 1.290 ± 0.23 2.603 ± 0.20 1.477 ± 0.11 14.63 ± 0.66 3.947 ± 0.12 
P19 67.97 ± 0.80 12.10 ± 1.62 ND 1.377 ± 0.13 1.643 ± 0.02 20.15 ± 0.43 4.547 ± 0.08 8.143 ± 1.19 
P20 45.50 ± 0.76 1.567 ± 0.15 0.510 ± 0.11 2.877 ± 0.17 1.540 ± 0.18 25.48 ± 2.14 6.313 ± 0.49 2.813 ± 0.22 
ND=Not detected 
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Table 4: Concentration (ppm) of various toxic heavy metals in finished dosage form of local antihypertensive herbal drug products 
 
ND= Not Detected 
 
 
 
 
 
 
 
  
Table 5: Daily intake of metals (µg/day) according to daily dose of herbal antihypertensive products 
         ND= Not Detected
Product 
Code Fe Cd Pb Cr Cu Mn Zn Ni 
P1 985.81±5.44 17.33±4.03 1.76±0.05 1.44±0.25 14.88±1.42 30.96±0.56 26.31±1.27 0.59±0.28 
P2 43.62±8.71 5.59±1.05 ND 15.88±3.96 0.38±0.19 10.33±0.08 0.34±0.10 2.53±0.12 
P3 828.27±15.53 2.27±1.00 6.29±0.52 12.43±2.13 6.40±0.71 ND 13.01±0.58 1.12±0.13 
P4 43.85±5.85 7.49±1.53 0.44±0.16 ND 1.01±0.03 6.57±0.84 4.82±1.66 1.20±0.66 
P5 1597.20±43.33 2.12±0.09 61.32±8.18 96.91±4.47 2.27±0.44 23.39±3.81 7.45±0.82 2.43±0.26 
P6 71.99±2.09 4.26±0.23 ND 10.2±6.25 1.62±0.23 15.42±1.13 6.51±1.02 7.37±0.26 
P7 267.87±33.34 5.38±0.30 3.34±0.68 0.33±0.16 2.59±0.13 11.67±1.0 9.19±0.41 6.57±0.18 
P8 66.36±22.82 8.38±2.10 1.00±0.02 3.14±0.01 1.86±0.10 5.17±0.68 20.78±1.22 22.76±0.21 
P9 1648.06±157.7 1.15±0.40 1.19±0.14 0.32±0.07 5.09±0.44 17.10±1.25 7.93±0.10 45.46±4.13 
P10 66.97±1.39 10.43±2.31 ND 1.16±0.09 1.33±0.40 18.84±0.21 3.88±0.43 7.47±1.28 
P11 312.11±10.09 39.53±6.56 2.01±0.17 ND 4.48±0.24 19.12±2.44 10.41±0.83 14.93±4.57 
P12 1568.23±5.49 32.31±4.01 ND 18.65±0.26 4.50±1.0 16.42±4.31 6.59±1.43 1.41±0.35 
P13 134.63±5.52 5.17±0.06 5.31±0.23 5.06±1.47 1.96±1.28 12.01±1.01 2.64±0.54 6.78±1.33 
P14 88.58±1.91 7.63±1.23 1.33±0.07 108.48±5.31 5.57±0.20 13.13±1.09 30.95±0.78 22.18±3.96 
P15 31.78±0.10 11.34±0.90 16.59±0.98 21.82±3.58 28.22±2.56 20.78±1.73 80.31±6.67 0.13±0.04 
P16 757.92±25.16 4.32±1.01 8.30±0.83 71.50±2.56 4.09±1.36 5.21±0.72 76.27±3.64 0.67±0.25 
P17 11.28±1.46 1.39±0.44 0.36±0.07 54.0±5.02 21.04±0.86 12.12±2.41 27.42±5.01 5.09±0.35 
P18 225.58±2.53 8.64±0.53 0.60±0.05 0.59±0.09 10.15±0.34 7.63±0.65 22.96±1.82 5.75±0.45 
P19 565.80±12.64 1.94±0.25 ND 1.40±0.22 2.50±0.44 1.24±0.19 13.29±2.39 4.24±0.55 
P20 43.16±3.37 1.16±0.13 0.47±0.12 2.84±0.25 1.39±0.19 21.81±2.37 6.31±1.26 2.41±0.47 
Product 
Code         Fe            Cd             Pb            Cr            Cu             Mn             Zn             Ni 
P1 288.68±4.17 5.07±1.13 0.51±0.08 0.42±0.13 4.35±0.17 9.06±0.03 7.70±0.75 0.17±0.05 
P 2 10.54±1.64 1.35±0.42 ND 3.83±0.06 0.09±0.03 2.16±0.39 0.083±0.47 0.61±0.42 
P 3 173.47±7.6 0.47±0.06 1.31±0.08 14.97±1.91 1.34±0.08 ND 2.72±0.71 0.23±0.71 
P 4 10.13±1.3 1.73±0.12 0.10±0.04 ND 0.23±0.02 1.51±0.73 1.11±0.50 0.27±0.02 
P 5 256.03±53.7 0.34±0.10 10.03±0.98 15.86±1.11 0.37±0.12 3.82±0.41 1.22±1.16 0.39±1.73 
P 6 25.28±5.38 1.49±0.41 ND 4.30±1.01 0.56±0.07 5.41±0.23 2.28±.61 2.59±0.75 
P 7 96.29±5.26 1.93±0.10 1.20±0.19 0.11±0.72 0.93±0.03 4.19±1.8 3.30±0.68 2.36±0.50 
P 8 7.023±1.95 0.88±0.09 0.10±0.08 0.33±0.04 0.19±0.03 0.54±0.20 2.20±1.16   1.48±0.21 
P 9 202.25±1.76 0.14±0.16 0.14±0.01 0.03±0.06 0.62±0.09 2.09±0.75 0.97±0.11 5.57±0.21 
P 10 13.40±1.43 2.08±0.21 ND 0.23±0.04 0.26±0.04 3.77±1.02 0.77±0.71 1.49±0.29 
P 11 57.70±3.96 7.30±0.87 0.37±0.05 ND 0.82±0.27 3.53±1.83 1.92±0.90 2.76±0.44 
P 12 562.74±3.66 11.59±0.72 ND 0.47±0.08 1.61±0.06 5.89±2.47 2.36±0.44 0.50±0.64 
P 13 29.94±0.75 1.15±0.30 1.18±0.47 1.12±0.48 0.43±0.74 2.67±0.83 0.58±0.67 1.50±0.45 
P 14 23.37±2.08 2.01±0.30 0.35±0.05 28.62±1.02 1.47±0.27 3.46±1.23 8.16±0.58 5.85±0.93 
P 15 2.81±0.45 1.00±0.07 1.47±0.03 1.93±0.29 2.50±0.62 1.84±0.24 7.11±0.06 0.01±0.0 
P 16 226.61±0.81 1.29±0.02 2.48±0.11 3.71±0.73 1.22±0.71 1.55±0.53 22.80±0.46 0.20±0.01 
P 17 2.93±0.17 0.36±0.02 0.09±0.03 14.03±0.56 5.47±0.17 3.15±1.16 7.12±0.64 1.32±0.12 
P 18 76.67±0.55 2.93±0.12 0.20±0.10 0.20±0.10 3.45±0.05 2.59±0.45 7.80±0.90 1.95±0.07 
P 19 204.39±3.90 0.70±0.10 ND 0.50±0.10 0.90±0.13 0.44±0.13 4.80±0.52 1.53±0.14 
P 20 13.62±0.62 0.36±0.07 0.15±0.05 0.89±0.42 0.43±0.16 6.88±0.94 1.99±0.58 0.76±0.07 
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Hardness of tablets 
 
Products P1, P3, P8, and P11 failed the hardness test, specified in Pharmacopeia (USP, 2014). 
 
Friability of tablets 
 
Table 2 shows that friability of tablets of Products (P3, P9 and P11) failed the test (USP, 2014). 
 
 Evaluation of toxic heavy metals by flame atomic absorption spectrophotometer 
 
 In medicine, heavy metals poisoning can possibly include excessive amounts of iron, cadmium, lead, manganese, 
chromium, copper, zinc and nickel (Luo et al., 2011, Järup, 2003, Ernst, 2002). Iron is an essential element but once in excess, 
poseses a threat to cells and tissues, and therefore iron homeostasis has to be tightly controlled. (Papanikolaou and Pantopoulos, 
2005). The recommended daily allowance of iron is 7-10 mg/day (Trumbo et al., 2001). All the tested products contained iron and 
the highest concentrations administered according to manufacturer dose were found in product P12 (562.74 µg/day) while lowest 
concentrations were found in product P15 (2.81 µg/day). Cadmium can cause severe complications and injuries to the tissues (Järup, 
2003). According to Food and drug administration (FDA) and World Health Organization (WHO) the daily intake of Cadmium 
should not exceed 0.07 mg/day. Product P12 after administration provides (11.59 µg/day). High concentrations of lead is associated 
with status epileptics, infant fatal encephalopathy, congenital paralysis, sensori-neural deafness and growth retardation (Meeting and 
Organization, 2007). From Table 4 it can be seen product P5 (10.03 µg/day) provides highest concentration of lead. Exposure to high 
levels of Chromium can cause lungs cancer and demitits. The daily permissible intake of Chromium is 0.03 mg/day for adults 
(Health and Services, 1993). Among the herbal drugs under test the highest concentration of Chromium was provided by P14 (28.62 
µg/day) after administration, while in product P9 it was found in permissible limits. However product P12 was found to have no 
traces of chromium. Copper is an essential element for human metabolism and in the synthesis of neurotransmitters (Health and 
Services, 1993). From Table 5 the daily consumption of copper from product P17 (5.47 µg/day) was the highest, while P2 (0.09 
µg/day) was found the lowest among all the tested products. Product P1 after administration according to prescribed dose provides 
(9.06 µg/day) Manganese, Product P2 has no manganese contents while product P19 gives the lowest concentration (0.44 µg/day).  
Manganese is also an essential element and the daily requirements for children are about 1.2-1.5 mg/day, 2.3 mg/day for men and 
1.8-2.0 mg/day for women (Normandin et al., 2004). The recommended daily allowance of Zinc for children is 4-5 mg/day while for 
adults it is 9-13 mg/day (Hotz and Brown, 2004).  Except Product P16 (22.80 µg/day) all other tested samples show nearly optimum 
concentrations of Zinc. Least concentrations were found in product P2 (0.083 µg/day). As shown in Table 5 Product P14 provides 
highest concentrations of nickel (5.85 µg/day) while product P15 was found to have limited amounts of nickel. According to the 
agency of toxic substances and disease registry (ATSDR) exposure to Nickel is commonly associated with allergic reactions, blood, 
stomach, liver and kidney disorder (Anke et al., 1995).  
 
Evaluation of allopathic drug contents using HPLC 
 
 Various allopathic drug contents of Ca+2 channel blockers (Amlodipine, Verapamil and Nifedipine) and a diuretic agent, 
Hydrochlorothiazide in combination with Amlodipine was detected and calculated for daily dose as recommended by the prescriber. 
From Table 6 it can be seen that raw material and the finished dosage form of the herbal products were found adulterated with 
allopathic contents. Higher concentration of adulterated allopathic contents of Amlpdopine administered according to manufacturer 
dose were found in P12 (20.30 mg/day), Verapamil in P2 (93.50 mg/day) and Nifedipine in P6 (38.65 mg/day). Products P4, P5 and 
P7 were found to have a combination of Amlopdipine and Hydrochlorothiazide and higher concentration were found in P5 (10.72 
mg/day, 24.75 mg/day). In some of the procured herbal remedies under test the finished dosage form do not have any traces of 
allopathic contents (Product P1, Product P6) but the raw materials of these products were found to have adulteration, which indicates 
that these remedies might be contaminated to enhance their pharmacological and therapeutic effects by quacks, which may lead to 
severe toxic effects.  
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Table 6: Identified adulterated allopathic contents in raw and finished dosage form of antihypertensive herbal product 
 
 
 
 
 
 
 
 
  
Figure 1: Chromatogram of Amlodipine Standard 
Product Code Identified 
Allopathic 
compound in 
Raw/Finished 
dosage form  
AML(Avg. 
mg/daily dose) 
VER (Avg. 
mg/daily dose) 
NFD (Avg. 
mg/daily dose) 
AML+HCT (Avg. 
mg/daily dose) 
P1 AML (R) 17.65±0.11 - - - 
P2 VER (F) - 93.50±0.40 - - 
P3 VER (F) - 86.55±0.34 - - 
P4 AML+HCT (F) - - - (9.96±0.12)+(23.84±0.99) 
P5 AML+HCT (F) - - - (10.72±0.20)+(24.75±0.27) 
P6 NFD(R) - - 38.65±0.5 - 
P7 AML+HCT (F) - - - 11.02±0.78+22.20±0.79 
P8 AML (F) 17.82±0.13 - - - 
P9 ND - - - - 
P10 ND - - - - 
P11 NFD (F) -  17.90±0.34 - 
P12 AML (F) 20.30±0.85 - - - 
P13 AML (F) 3.23±0.23  -  
P14 ND - - - - 
P15 ND - - - - 
P16 ND - - - - 
P17 NID - - - - 
P18 VER(F) - 80.32±0.48 - - 
P19 ND - - - - 
P20 ND - - - - 
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Figure 2: Chromatogram of Amlodipine identified in antihypertensive Product P1 
 
 
 
 
Figure 3:  Chromatogram of Amlodipine identified in antihypertensive Product P8 
 
 
 
Figure 4: Chromatogram of Amlodipine identified in antihypertensive Product P12 
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Figure 5: Chromatogram of Amlodipine identified in antihypertensive Product P13 
 
Figure 6: Chromatogram of Verapamil standard 
 
 
 
 
Figure 7: Chromatogram of Verapamil identified in antihypertensive Product P2 
 
Figure 8: Chromatogram of Verapamil identified in antihypertensive Product P3 
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Figure 9: Chromatogram of Verapamil identified in antihypertensive Product P18 
 
 
Figure 10: Chromatogram of Nifedipine Standard 
 
 
Figure 11: Chromatogram of Nifedipine identified in antihypertensive Product P6 
 
 
Figure 12: Chromatogram of Nifedipine identified in antihypertensive Product P11 
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Figure 13: Chromatogram of Amlodipine+Hydrochlorothiazide identified in Product P4 
 
 
Figure 14: Chromatogram of Amlodipine+Hydrochlorothiazide identified in Product P5  
 
 
Figure 15: Chromatogram of Amlodipine+Hydrochlorothiazide identified in herbal Product P7 
 
Conclusion 
 
 Societal laws allow for the marketing of herbal remedies without subjection or subjecting them to the same regulations 
required for the safety and efficacy of allopathic drug products. As the herbal remedies are often adulterated by quacks to enhance 
their pharmacological effects and this can be seen from the results, which clearly indicate that the pharmaceutical quality control 
parameters deviate the permissible pharmacopeial limits, heavy metals were quantified in toxic limits and adulterated allopathic drug 
contents were detected in raw materials and finished dosage forms of antihypertensive herbal products. Therefore, evidence of 
adulterant profile of the herbal products should be obtained both in raw and finished dosage form by well-designed analytical 
procedures. This will help to decrease the toxic effects of these remedies and increase the commercialization, internationalization 
and harmonization of antihypertensive herbal products. 
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